09:27 uur 17-07-2020

De eerste klinische fase III-studie van COVID-19 geïnactiveerd vaccin begint in de VAE

ABU DHABI, Verenigde Arabische Emiraten – (BUSINESS WIRE) – De eerste WHO heeft een wereldwijde klinische fase III-studie van Sinopharm CNBG’s geïnactiveerd vaccin ter bestrijding van COVID-19 gestart in Abu Dhabi, geïnspireerd door de toewijding van de VAE om de pandemie te overwinnen door middel van een wereldwijde gezamenlijke inspanning.

HIJ. Sheikh Abdullah bin Mohammed Al Hamed, voorzitter van het ministerie van Volksgezondheid, Abu Dhabi, was de eerste ter wereld die de proef begon met een fase III-geïnactiveerd vaccin voor COVID-19 dat het resultaat is van een samenwerkingsverband tussen de in Abu Dhabi gevestigde G42 Gezondheidszorg en Sinopharm CNBG, ‘s werelds zesde grootste vaccinfabrikant.

De VAE is geselecteerd om de proeven uit te voeren, aangezien het land de thuisbasis is van meer dan 200 nationaliteiten, waardoor robuust onderzoek over meerdere etniciteiten mogelijk is en de haalbaarheid voor wereldwijde toepassing wordt vergroot. Ze worden beheerd door Abu Dhabi Health Services (SEHA), die klinische faciliteiten bieden.

World’s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE

ABU DHABI, United Arab Emirates–(BUSINESS WIRE)– The first WHO enlisted global clinical Phase III trial of Sinopharm CNBG’s inactivated vaccine to combat COVID-19 has started in Abu Dhabi, inspired by the UAE Leadership’s commitment to overcome the pandemic through a global collaborative effort.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200717005085/en/

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of Department of Health, Abu Dhabi, being administered the world’s first clinical Phase III trial of inactivated vaccine to combat COVID-19 (Photo - AETOSWire).

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of Department of Health, Abu Dhabi, being administered the world’s first clinical Phase III trial of inactivated vaccine to combat COVID-19 (Photo – AETOSWire).

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase III inactivated vaccine for COVID-19 that is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer.

The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application. They are being operated by Abu Dhabi Health Services (SEHA) who are providing clinical facilities.

UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate and G42 Healthcare and SEHA are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.

Chairperson of the UAE National COVID-19 Clinical Management Committee Dr. Nawal Ahmed Alkaabi said: “Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. We are proud to facilitate the testing process that if successful leads to the manufacture of a vaccine.”

It follows successful phase I and II trials by Sinopharm in China, resulting in 100% of volunteers generating antibodies.

G42 Healthcare CEO Ashish Koshy said: “We are enormously proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials.”

Jingjin Zhu, President, Biological products, Sinopharm CNBG added: “The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background. We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide.”

*Source: AETOSWire

Contacts

Tasneem Riyaz

g42@apcoworldwide.com

Check out our twitter: @NewsNovumpr